BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Stock Has Consensus Target Price of $21.11

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) have earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $21.11.

A number of analysts have weighed in on BBOT shares. JPMorgan Chase & Co. reduced their price target on shares of BridgeBio Oncology Therapeutics from $25.00 to $23.00 and set an “overweight” rating for the company in a report on Friday, September 11th. Leerink Partners dropped their price objective on shares of BridgeBio Oncology Therapeutics to $27.00 and set an “outperform” rating on the stock in a report on Thursday, September 10th. Stifel Nicolaus cut their price objective on shares of BridgeBio Oncology Therapeutics from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, September 9th. Oppenheimer decreased their target price on BridgeBio Oncology Therapeutics to $16.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 20th. Finally, Canaccord Genuity Group lowered their price target on BridgeBio Oncology Therapeutics from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, September 9th.

BridgeBio Oncology Therapeutics Price Performance

Shares of BBOT stock opened at $2.04 on Monday. BridgeBio Oncology Therapeutics has a 12 month low of $1.98 and a 12 month high of $14.87. The firm has a market cap of $163.55 million, a PE ratio of -0.74 and a beta of 0.86. The stock has a 50 day moving average of $4.30 and a 200-day moving average of $7.93.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($705.20) earnings per share (EPS) for the quarter. As a group, equities analysts predict that BridgeBio Oncology Therapeutics will post -2.81 EPS for the current fiscal year.

Institutional Trading of BridgeBio Oncology Therapeutics

Several institutional investors have recently modified their holdings of the company. Regents of The University of California bought a new stake in BridgeBio Oncology Therapeutics in the 3rd quarter valued at $10,289,000. Opaleye Management Inc. lifted its holdings in shares of BridgeBio Oncology Therapeutics by 1,213.8% during the 2nd quarter. Opaleye Management Inc. now owns 700,000 shares of the company’s stock worth $5,334,000 after acquiring an additional 646,718 shares during the period. Granahan Investment Management LLC bought a new position in shares of BridgeBio Oncology Therapeutics during the 1st quarter worth about $2,068,000. Renaissance Technologies LLC lifted its holdings in shares of BridgeBio Oncology Therapeutics by 37.1% during the 1st quarter. Renaissance Technologies LLC now owns 101,900 shares of the company’s stock worth $912,000 after acquiring an additional 27,600 shares during the period. Finally, Tidal Investments LLC boosted its position in shares of BridgeBio Oncology Therapeutics by 13.6% during the 2nd quarter. Tidal Investments LLC now owns 93,339 shares of the company’s stock valued at $711,000 after acquiring an additional 11,167 shares in the last quarter. Institutional investors and hedge funds own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with genetically driven cancers. The company is part of the broader BridgeBio platform, which supports the development of therapies for diseases linked to well-defined biological targets.

Its oncology programs are centered on small-molecule therapies intended to address cancer-causing genetic alterations, including targets that have historically been difficult to treat.